A flurry of tech and life sciences startup financings has kept us busy on the deals news front.
—Andover, MA-based NewRiver, a maker of investor disclosure software, said it will be acquired for $77 million by Lake Success, NY-based Broadridge Financial Solutions (NYSE: BR). NewRiver’s investors include Ironside Ventures, FirstMark Capital, and Lazard Technology Partners.
—PatientsLikeMe, a Cambridge, MA-based provider of social networking platforms for discussion among people with the specific illnesses, raised $8 million of an equity round that could total $30 million.
—Cambridge-based Anchor Therapeutics, formerly Ascent Therapeutics, brought in $10 million in Series B funding from return investors TVM Capital, HealthCare Ventures, and the Novartis Option Fund. The company raised $19 million in its first round of venture funding in 2008.
—Vanu, a Cambridge-based maker of mobile software to power wireless radios, pulled in $2.1 million of a planned $5.2 million round of equity, options, and warrants. The startup raised $32 million in Series B money last year from Charles River Ventures, Norwest Venture Partners, and Tata Capital.
—Enterprise database performance software maker Tokutek, with offices in Lexington, MA and New York City, grabbed $2.8 million of a planned $3.7 million equity-based financing.
—Needham, MA-based Visual IQ, a maker of enterprise marketing analytics software, brought in $3 million from San Francisco’s Fog City Capital. The financing represents the company’s first institutional funding round.
—RatePoint, a Needham maker of online platforms to help businesses manage customer feedback, said it raised a $7 million Series C financing from Prism VentureWorks, .406 Ventures, and Castile Ventures. The deal brings the company’s funding pot to $23.5 million.
—After a busy month of deal-making in June, Massachusetts startups brought in a much smaller total of $131 million in July, according to data from CB Insights. The month’s biggest deal was a $24 million Series A round for Euthymics Bioscience.
—Cambridge-based Taligen Therapeutics received a $10 million investment to put toward developing its drug for targeting autoimmune disease. The financing comes from Alta Partners, Clarus Ventures, High Country Venture, and Sanderling Ventures.
—Cambridge biotech Aileron Therapeutics inked a deal with Swiss drug and diagnostics company Roche that could be worth up to $1.1 billion. Under the agreement, Roche will provide at least $25 million in technology access fees and R&D support to Aileron, to develop and commercialize a new class of drugs called “stapled peptides.”
—Cambridge-headquartered fund manager C Change Investments partnered on a new fund with Vanterra Capital, raising $100 million in an initial close earlier in August. The Vanterra C Change Transformative Energy & Materials Fund I will invest in companies whose technologies help make industrial operations more energy efficient.
—New medical imaging startup Photo Diagnostic Systems, of Danvers, MA, nailed down $5 million in equity-based funding. Analogic and NeuroLogica founder Bernard Gordon, who bought the assets of the now defunct Photo Detection Systems, started the new company by investing through the Gordon Charitable Remainder Trust.